第七因子缺乏症的临床,实验室和分子方面
Francesco Bernardi1, Guglielmo Mariani2
1Department of Life Science and Biotechnology, University of Ferrara, Ferrara, Italy.
Seminars in thrombosis and hemostasis
|August 29, 2024
概括
遗传性第七因子 (FVII) 缺乏症是一种常见的出血障碍,症状可变. 了解FVIIa-TF复合物有助于管理患者并开发改善的治疗方法来治疗因子VII缺乏症.
科学领域:
- 血液学 血液学 血液学
- 遗传学 遗传学 是一个
- 分子生物学分子生物学
背景情况:
- 遗传性第七因子 (FVII) 缺乏是最常见的遗传性凝血障碍.
- 它呈现出广泛的出血症状,从轻微到危及生命的.
- 血FVII水平的临床值及其与表型的相关性仍然不清楚.
研究的目的:
- 阐明FVIIa-TF复合体在理解临床FVII缺陷表型中的作用.
- 审查目前和新兴的FVII缺陷管理策略.
- 讨论FVII缺陷的遗传基础和种群遗传学.
主要方法:
- 对FVII缺陷,FVIIa-TF复合体和F7基因突变的现有文献的审查.
- 与FVII水平和遗传变异相关的临床发现的分析.
- 综合有关诊断和治疗进展的信息.
主要成果:
- FVIIa-TF复合体对于FVII的前凝活性和解释临床表现至关重要.
- 重组FVIIa是有效的,但半衰期很短;新的延长半衰期治疗正在出现.
- 数以千计的FVII缺陷患者已被遗传特征,揭示了多种多样的F7突变和特定人群的变异.
结论:
- 了解FVIIa-TF相互作用可以改善FVII缺陷的管理.
- 遗传因素,包括常见的多态性,显著影响FVII水平和出血风险.
- 持续的研究和FVII缺乏症的表征对于患者护理至关重要.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
654
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
654
Extrinsic and Intrinsic Pathways of Hemostasis
6.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
6.5K
Disorders of Hemostasis
754
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
754
Coagulation
5.6K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
5.6K
Structure and Function of Platelets
1.1K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.1K
Clot Retraction and Fibrinolysis
4.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
4.9K


